
TDOC
Teladoc Health Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
8.250
Open
8.250
VWAP
8.14
Vol
6.33M
Mkt Cap
1.44B
Low
7.970
Amount
51.56M
EV/EBITDA(TTM)
10.11
Total Shares
169.59M
EV
1.79B
EV/OCF(TTM)
5.95
P/S(TTM)
0.55
Teladoc Health, Inc. provides virtual healthcare services. The Company operates through two segments: Teladoc Health Integrated Care (Integrated Care) and BetterHelp. The Integrated Care segment includes a suite of global virtual medical services including general medical, medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. Services in this segment are distributed primarily on a business-to-business (B2B) basis. The BetterHelp segment primarily consists of its direct-to-consumer (D2C) mental health platform. The online counseling and therapy services are provided via its network of over 35,000 licensed clinicians, leveraging its platform for Web, mobile app, phone, and text-based interactions. Its Teladoc Health family of brands, including Teladoc and BetterHelp, deliver access to advice and resolution for an array of healthcare needs.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
637.18M
-0.52%
-0.228
-7.18%
627.76M
-1.99%
-0.228
+33.43%
622.01M
-3.18%
-0.302
+12.66%
Estimates Revision
The market is revising Downward the revenue expectations for Teladoc Health, Inc. (TDOC) for FY2025, with the revenue forecasts being adjusted by -0.2% over the past three months. During the same period, the stock price has changed by 14.53%.
Revenue Estimates for FY2025
Revise Downward

-0.2%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+6.59%
In Past 3 Month
Stock Price
Go Up

+14.53%
In Past 3 Month
16 Analyst Rating

4.76% Upside
Wall Street analysts forecast TDOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TDOC is 8.59 USD with a low forecast of 7.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
14 Hold
0 Sell
Hold

4.76% Upside
Current: 8.200

Low
7.00
Averages
8.59
High
12.00

4.76% Upside
Current: 8.200

Low
7.00
Averages
8.59
High
12.00
Mizuho
Steven Valiquette
Neutral
initiated
$10
2025-07-25
New
Reason
Mizuho
Steven Valiquette
Price Target
$10
2025-07-25
New
initiated
Neutral
Reason
Mizuho analyst Steven Valiquette initiated coverage of Teladoc with a Neutral rating and $10 price target. The firm is encouraged by Teladoc's growth in its Integrated Care segment but is concerned about the potential pace of BetterHelp attrition over the near term. The company's customer acquisition costs remain elevated, and consumer sentiment remains well below historical averages in 2025, the analyst tells investors in a research note.
BofA
Neutral
maintain
$7
2025-07-03
Reason
BofA
Price Target
$7
2025-07-03
maintain
Neutral
Reason
BofA raised the firm's price target on Teladoc to $8.75 from $7 and keeps a Neutral rating on the shares. Teladoc's recent acquisitions of Catapult and Uplift provide optionality to drive higher revenue per member, but it will take both time and execution to improve the revenue growth outlook, the analyst tells investors in a research note. BofA remains cautious on full-year guidance and momentum into 2026 but views recent acquisitions as potential catalysts for growth.
BofA
Neutral
downgrade
$8 -> $7
2025-05-28
Reason
BofA
Price Target
$8 -> $7
2025-05-28
downgrade
Neutral
Reason
BofA lowered the firm's price target on Teladoc to $7 from $8 and keeps a Neutral rating on the shares. In April, global BetterHelp MAUs declined 6.1% year-over-year, further decelerating from low single-digit declines in the prior month, according to the analyst, who cites lower peer multiples for the firm's lowered price target. The firm remains cautious on the near-term outlook, but could see investments for future growth driving greater patient engagement over time, the analyst added.
Truist
Hold
downgrade
$10 -> $9
2025-05-27
Reason
Truist
Price Target
$10 -> $9
2025-05-27
downgrade
Hold
Reason
Truist lowered the firm's price target on Teladoc to $9 from $10 and keeps a Hold rating on the shares. The firm is updating its model after the company's Q1 results with expectations of slightly lower 2026 EBITDA, the analyst tells investors in a research note. Longer term, Truist notes that with about 90M U.S. members having access to its offerings, Teladoc has the scale and depth to take advantage of various growth opportunities across the healthcare continuum.
Citi
Neutral
downgrade
$11
2025-04-25
Reason
Citi
Price Target
$11
2025-04-25
downgrade
Neutral
Reason
Citi lowered the firm's price target on Teladoc to $8.75 from $11 and keeps a Neutral rating on the shares. The firm also added an "upside 30-day short-term view" on the shares. It is likely that BetterHelp beats on sales this quarter, the analyst tells investors in a research note. Citi does not expect any change to Teladoc's guidance and, given consumer spending concerns, it thinks management will strike a cautious tone. However, given bearish sentiment, "this should be good enough" for a positive stock price reaction, contends the firm.
Jefferies
Glen Santangelo
Hold
Maintains
$10 → $8
2025-04-21
Reason
Jefferies
Glen Santangelo
Price Target
$10 → $8
2025-04-21
Maintains
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Teladoc Health Inc (TDOC.N) is -7.58, compared to its 5-year average forward P/E of -50.78. For a more detailed relative valuation and DCF analysis to assess Teladoc Health Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-50.78
Current PE
-7.58
Overvalued PE
20.68
Undervalued PE
-122.24
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
40.10
Current EV/EBITDA
6.46
Overvalued EV/EBITDA
83.97
Undervalued EV/EBITDA
-3.77
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
4.64
Current PS
0.57
Overvalued PS
9.95
Undervalued PS
-0.67
Financials
Annual
Quarterly
FY2025Q1
YoY :
-2.59%
629.37M
Total Revenue
FY2025Q1
YoY :
-28.72%
-54.94M
Operating Profit
FY2025Q1
YoY :
+13.58%
-93.01M
Net Income after Tax
FY2025Q1
YoY :
+8.16%
-0.53
EPS - Diluted
FY2025Q1
YoY :
-41.09%
-15.67M
Free Cash Flow
FY2025Q1
YoY :
-8.00%
54.76
Gross Profit Margin - %
FY2025Q1
YoY :
-7.22%
7.07
FCF Margin - %
FY2025Q1
YoY :
+16.65%
-14.78
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 368.49% over the last month.
Sold
0-3
Months
239.0K
USD
6
3-6
Months
533.3K
USD
8
6-9
Months
487.7K
USD
7
0-12
Months
193.8K
USD
12
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
30.8K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
213.7K
Volume
1
6-9
Months
350.0K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
310.6K
Volume
Months
6-9
2
2.5M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 368.49% over the last month.
Sold
0-3
Months
239.0K
USD
6
3-6
Months
533.3K
USD
8
6-9
Months
487.7K
USD
7
0-12
Months
193.8K
USD
12
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
30.8K
USD
Months
TDOC News & Events
Events Timeline
2025-06-23 (ET)
2025-06-23
10:18:33
Teladoc 'a coiled spring' whose CEO 'just flipped the script,' Citron says


2025-04-30 (ET)
2025-04-30
16:12:57
Teladoc acquires UpLift Health for $30M in cash

2025-04-30
16:11:54
Teladoc sees Q2 EPS (40c)-(20c), consensus (26c)

Sign Up For More Events
Sign Up For More Events
News
4.0
07-25BenzingaThis Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
8.0
07-24TipRanksOptions Volatility and Implied Earnings Moves Today, July 24, 2025
3.5
07-15TipRanksOpenEvidence Is Quietly Becoming the Google of Medicine
Sign Up For More News
People Also Watch

GO
Grocery Outlet Holding Corp
13.880
USD
-0.79%

HMN
Horace Mann Educators Corp
40.640
USD
-1.79%

PLAB
Photronics Inc
19.720
USD
+0.61%

GPCR
Structure Therapeutics Inc
17.940
USD
-1.81%

NCTY
The9 Ltd
9.130
USD
-6.45%

HIMX
Himax Technologies Inc
9.540
USD
-0.31%

VECO
Veeco Instruments Inc
20.820
USD
+1.12%

INFN
Infinera Corp
0
USD
-0.15%

CTS
CTS Corp
41.430
USD
-1.36%

CDRE
Cadre Holdings Inc
33.890
USD
+0.56%
FAQ

What is Teladoc Health Inc (TDOC) stock price today?
The current price of TDOC is 8.2 USD — it has increased 0 % in the last trading day.

What is Teladoc Health Inc (TDOC)'s business?

What is the price predicton of TDOC Stock?

What is Teladoc Health Inc (TDOC)'s revenue for the last quarter?

What is Teladoc Health Inc (TDOC)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Teladoc Health Inc (TDOC)'s fundamentals?

How many employees does Teladoc Health Inc (TDOC). have?
